JUAN
PASQUAU LIAÑO
Investigador en el periodo 2022-2023
Hospital Universitario Reina Sofia
Córdoba, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (20)
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2018
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
2017
-
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study
HIV Medicine, Vol. 18, Núm. 7, pp. 482-489
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes
Antiviral Research, Vol. 120, pp. 79-84
-
The Efficacy and Safety of Maraviroc Addition to a Stable Antiretroviral Regimen in Subjects with Suppressed Plasma HIV-RNA is Not Influenced by Age
AIDS Research and Human Retroviruses, Vol. 31, Núm. 9, pp. 893-897
2013
-
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of staphylococcus aureus bacteremia
Clinical Infectious Diseases, Vol. 57, Núm. 9, pp. 1225-1233
2011
-
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/Hepatitis C Virus-Coinfected Patients
AIDS Patient Care and STDs, Vol. 25, Núm. 7, pp. 395-402
2010
2009
-
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 1, pp. 178-183
2008
-
Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
2007
-
Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 5, pp. 305-310
2005
-
Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study
HIV Clinical Trials, Vol. 6, Núm. 6, pp. 320-328
2003
-
Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el vih con anergia cutánea
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 21, Núm. 6, pp. 287-292
2000
-
Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in naive human immunodeficiency virus-infected patients from Andalucía (Spain)
Medicina Clinica, Vol. 115, Núm. 11, pp. 423-425
1999
-
Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
AIDS, Vol. 13, Núm. 9, pp. 1063-1069
1998
-
Comparative study of bacteremias caused by Enterococcus spp. with and without High-level resistance to gentamicin
Journal of Clinical Microbiology, Vol. 36, Núm. 2, pp. 520-525
1996
-
Prospective evaluation of fever of unknown origin in patients infected with the human immunodeficiency virus
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 15, Núm. 9, pp. 705-711